section name header

Pronunciation

a-zill-SAR-tan

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: angiotensin II receptor antagonists

Indications

REMS


Action

  • Blocks vasoconstrictor and aldosterone-producing effects of angiotensin II at receptor sites, including vascular smooth muscle and the adrenal glands.
Therapeutic effects:
  • Lowering of BP.

Pharmacokinetics

Absorption: Azilsartan medoxomil, a prodrug, is hydrolyzed in the GI tract to azilsartan, the active component. 60% is absorbed from the GI tract.

Distribution: Approximately 16 L.

Protein Binding: 99%.

Metabolism/Excretion: 50% metabolized by the liver, primarily by the CYP2C9 enzyme system. 55% eliminated in feces, 42% in urine (15% as unchanged drug).

Half-Life: 11 hr.

Time/Action Profile

(effect on BP)

ROUTEONSETPEAKDURATION
POwithin 2 hr18 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension

F and E: hyperkalemia

GI: diarrhea, nausea

GU: renal impairment

MS: muscle spasm

Neuro: dizziness, fatigue, weakness

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Edarbi